Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
11 Cards in this Set
- Front
- Back
Immunopharmacology Drugs
- 6 of them |
- cyclosporine
- sirolimus - prednisone - cyclophosphamide - methotrexate - mycophenolate Mofetil |
|
Purpose of Immunosuppressive drugs
|
- prevent organ rejection
- tx of autoimmune diseases such as: MS, lupus, rhuematoid arthritis, crohn's disease, typeI diabetes |
|
Cell basis for rejection
|
- antigen presenting cell (from donor organ) activates Tcells
- T cells produce INTERLEUKIN 2 - IL2 stimulates production of immune cells - activate immune cells attach the transplanted organ! |
|
Molecular basis for rejection
|
- see pg 103 in notes
- IL-1 to the T cell - Nuclear factor of activaed T cells (when this interacts with calcineurin, it can make IL-2 with is released and stimulates proliferation of immune cells |
|
Prednisone
|
- works at molecular level
- blocks IL-1 from entering the T-cell and inhibits cytokine production - adverse effects: insomnia, hypomania, ulcers |
|
Cyclosporine
|
- block calcineurin from phosporylating NFAT
- adverse effects : nephrotoxicity, hepatotoxicity, neurotoxicity |
|
Sirolimus
|
- blocks mTOR from signaling cell proliferation
- adverse effects; hyperlipidemia! |
|
Cyclophophamide
Methotrexate Mycophenolate |
- these block cell proliferation after mTOR has already signaled
-mycophenolate; adverse effect- myelosuppression (proliferation associated toxicities) |
|
Muromonab-CD3
(antibody) |
- binds CD3 on surface of Tcells and inhibits function
- used to treat ACUTE TRANSPLANT REJECTION |
|
Anti-IL-2 receport antibodies
(Daclizumab) |
- blocks IL-2 receptor activation, thus blocking Tcell activation
- used to treat ACUTE TRANSPLANT REJECTION |
|
Rh(D) immune globulin
|
- Rh(-) mother wil produce antibodies to Rh(+) baby's erythrocytes
- Rh immune globulin given to mother after birth - this will lyse erythrocytes from baby before mother can generate an immune response |